Thermo Fisher boosts clinical supply chain and distribution services in Europe
Two new facilities in Germany will provide clinical supply and cold chain services to support growing demand
Thermo Fisher Scientific has expanded its pharma services footprint with two new facilities in Rheinfelden and Weil am Rhein, Germany to meet accelerating demand for robust clinical supply chain services throughout Europe.
According to the European Medicines Agency (EMA), today's clinical supply chain and logistics market in Europe is expected to double by 2025 and more than triple by 2030. Approximately 4,000 clinical trials are conducted each year in Europe, which is 20% of the global clinical trials market.
The Rheinfelden site, which opens later this month, and the Weil am Rhein site, scheduled to open in January 2021, will, therefore, bring much-needed clinical supply chain continuity, and specialized cold chain and cryogenic expertise.
The new 86,000-sq. ft (8,000-m2) facility in Rheinfelden, significantly increases the company's footprint for secondary packaging, storage, logistics and distribution of clinical supplies to investigator sites across Europe.
Featuring highly automated technology in a fully scalable, mixed-use space, the site will serve as a strategic logistics hub for shipping by road or air. Furthermore, its central location will help expedite clinical trial therapies to patients.
In Weil am Rhein, the new 9,600-sq. ft (890-m2) cryocenter provides specialized ultra-low-temperature, cryogenic storage and cold chain expertise for clinical supply chain needs for cell and gene-based therapies, including COVID-19 vaccine candidates.
The cryocenter will support ultra-low temperature storage, packaging, labeling, and distribution required by vaccine and cell and gene therapy innovators. The site will feature -80 °C freezers, liquid nitrogen (LN2) cryogenic storage tanks and walk-in 2–8 °C and -20 °C cold storage technology.
The new Rheinfelden and Weil am Rhein facilities are strategically located in the Baden region of Germany and in close proximity to the company's existing clinical services sites in Basel, Switzerland, and Horsham, UK, as well as to its dedicated cell and gene therapy facilities in Bishop's Stortford and Stevenage, UK.
Mike Shafer, senior vice president and president, pharma services, Thermo Fisher Scientific, said: "These facilities, combined with our established regulatory expertise, will give customers the continuity and in-region capabilities to support clinical trials across multiple therapy areas."
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance